FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
FDA PDUFA Goal Date Set for October 17, 2026 PITTSBURGH, Feb. 25, 2026 /PRNewswire/ —Â Viatris Inc. (Nasdaq: VTRS),…